title: [Effects of PreS2 synthetic peptides on infiltrating T lymphocyte subgroups expression in hepatocellular carcinoma].
abstract: OBJECTIVE
  To explore whether PreS2 can change the percentage of T lymphocyte subgroups and the ration of CD4+/CD8+ in hepatocellular carcinoma (HCC) caused by HBV.
  
  
  METHODS
  The P120-146 region composed by the way of Merrifield, which was the most intensive antigen in PreS2 peptides, served as the antigen after dissolved in 0.01 mol/L PBS. 12 patients were chosed as the subjects, who were pathologically diagnosed as HCC after operation, were HBsAg-, HBeAg-, anti-HBc, and HBV DNA positive in serum, and expressed HBsAg in HCC tissue. The monocytes were isolated and cultured in 96 microplate with 1x 10(6) cells in every well, then the PreS2 synthetic peptides was added in at the doses of 1microg, 5microg, and 10microg, also IL-2 with 500 U was added in. Seven days later, the percentage of CD3+, CD4+, CD8+, and the ratio of CD4+/CD8+ were detected.
  
  
  RESULTS
  It was found that the percentage of CD4+ increased significantly (t = 3.508, P < 0.01), and the ratio of CD4+/CD8+ decreasedly obviously (t = 2.235, P < 0.05) in the 5microg PreS2 synthetic peptides group, compared with those in the control group. The percentage of CD3+ rised markedly in the IL-2 group, compared with that in the control group.
  
  
  CONCLUSIONS
  With proper doses, PreS2 is capable of changing the expression of T lymphocyte subgroups in HCC tissue, increasing the percentage of CD4+ obviously and changing the motionless state of CD8+, to make the carcinoma cell killed through the action of CD4+ and CD8+.
authors.affiliation: *Department of Gastroenterology, Nanjiang County Hospital,Sichuan Province, Nanjiang 636600, China.
authors.forename: Shi-cheng
authors.initials: SC
authors.lastname: Zheng
authors.forename: Xiao-yu
authors.initials: XY
authors.lastname: Wei
authors.forename: Chao-bin
authors.initials: CB
authors.lastname: Xu
authors.forename: Hui-qin
authors.initials: HQ
authors.lastname: Xie
mesh_terms: D000595:Amino Acid Sequence; D016516:CD4-CD8 Ratio; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D006514:Hepatitis B Surface Antigens / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects* / Q000276:immunology; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000494:pharmacology*; D011498:Protein Precursors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D006514:Hepatitis B Surface Antigens; D010446:Peptide Fragments; D011498:Protein Precursors; C050807:presurface protein 2, hepatitis B surface antigen